Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01239342 · ClinicalTrials.gov registry record · Phase 2
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01239342: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01239342 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01239342, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This randomized phase II trial studies the side effects and how well Akt inhibitor MK2206 or everolimus works in treating patients with kidney cancer that does not respond to treatment. Akt inhibitor MK2206 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Everolimus may also stop the growth of kidney cancer by blocking blood flow to the tumor. It is not yet known whether Akt inhibitor MK2206 or everolimus is more effective in treating kidney cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Everolimus
- DRUG Akt Inhibitor MK2206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2011-01-27 |
| Est. Completion | 2018-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01239342
The ClinicalTrials.gov registry entry for NCT01239342 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01239342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01239342 about?
NCT01239342 is a clinical study titled "Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer". This randomized phase II trial studies the side effects and how well Akt inhibitor MK2206 or everolimus works in treating patients with kidney cancer that does not respond to treatment. Akt inhibitor MK2206 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for ...
What is the current status of trial NCT01239342?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2011-01-27. Estimated completion is 2018-09-19.
What interventions are being tested in trial NCT01239342?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Everolimus (DRUG), Akt Inhibitor MK2206 (DRUG).
Who is sponsoring clinical trial NCT01239342?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.